Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
N Perico, M Cortinovis, F Suter… - The Lancet Infectious …, 2023 - thelancet.com
Summary COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of
symptom severity that requires varying amounts of care according to the different stages of …
symptom severity that requires varying amounts of care according to the different stages of …
Dexamethasone for severe COVID-19: how does it work at cellular and molecular levels?
The coronavirus disease 2019 (COVID-19) caused by infection of the severe respiratory
syndrome coronavirus-2 (SARS-CoV-2) significantly impacted human society. Recently, the …
syndrome coronavirus-2 (SARS-CoV-2) significantly impacted human society. Recently, the …
Dexamethasone impairs the expression of antimicrobial mediators in lipopolysaccharide-activated primary macrophages by inhibiting both expression and function of …
JD O'Neil, OO Bolimowska, SA Clayton… - Frontiers in …, 2023 - frontiersin.org
Glucocorticoids potently inhibit expression of many inflammatory mediators, and have been
widely used to treat both acute and chronic inflammatory diseases for more than seventy …
widely used to treat both acute and chronic inflammatory diseases for more than seventy …
OM-85 Broncho-Vaxom®, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells
L Fang, L Zhou, M Tamm, M Roth - Biomedicines, 2021 - mdpi.com
In clinical studies, OM-85 Broncho-Vaxom®, a bacterial lysate, reduced viral respiratory tract
infection. Infection of epithelial cells by SARS-CoV-2 depends on the interaction of its spike …
infection. Infection of epithelial cells by SARS-CoV-2 depends on the interaction of its spike …
Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence
R Sarzani, F Spannella, F Giulietti, C Di Pentima… - Internal and Emergency …, 2022 - Springer
Since the publication of the RECOVERY trial, the use of glucocorticoid drugs (GC) has
spread for the treatment of severe COVID-19 worldwide. However, the benefit of …
spread for the treatment of severe COVID-19 worldwide. However, the benefit of …
Regulation of tissue immune responses by local glucocorticoids at epithelial barriers and their impact on interorgan crosstalk
The anti-inflammatory role of extra-adrenal glucocorticoid (GC) synthesis at epithelial
barriers is of increasing interest with regard to the search for alternatives to synthetic …
barriers is of increasing interest with regard to the search for alternatives to synthetic …
Exposing the two contrasting faces of STAT2 in inflammation
P Duodu, G Sosa, J Canar, O Chhugani… - Journal of Interferon & …, 2022 - liebertpub.com
Inflammation is a natural immune defense mechanism of the body's response to injury,
infection, and other damaging triggers. Uncontrolled inflammation may become chronic and …
infection, and other damaging triggers. Uncontrolled inflammation may become chronic and …
Calcifediol or Corticosteroids in the Treatment of COVID-19: An Observational Study
M Entrenas-Castillo, LM Entrenas-Costa, MP Pata… - Nutrients, 2024 - mdpi.com
Medical treatment of coronavirus 19 disease (COVID-19) is a therapeutic challenge. The
available data strongly suggest that calcifediol treatment may reduce the severity of COVID …
available data strongly suggest that calcifediol treatment may reduce the severity of COVID …
A distinct dexamethasone-dependent gene expression profile in the lungs of COVID-19 patients
The effects of dexamethasone (DXM) treatment on pulmonary immunity in COVID-19–
associated acute respiratory distress syndrome (CARDS) remain insufficiently understood …
associated acute respiratory distress syndrome (CARDS) remain insufficiently understood …
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma
RJ Russell, LP Boulet, CE Brightling… - European …, 2024 - Eur Respiratory Soc
Asthma is a disease of heterogeneous pathology, typically characterised by excessive
inflammatory and bronchoconstrictor responses to the environment. The clinical expression …
inflammatory and bronchoconstrictor responses to the environment. The clinical expression …